Advisory Alpha, LLC Arcellx, Inc. Transaction History

Advisory Alpha, LLC

$2.78 Billion
Q3 2024

A detailed history of Advisory Alpha, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Advisory Alpha, LLC holds 3,000 shares of ACLX stock, worth $226,620. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,000

Holding current value

$226,620

% of portfolio

0.01%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 12, 2024	BUY	$50.91 - $86.61 $152,730 - $259,830	3,000 New	3,000 $250,000
Q1 2024 May 06, 2024	BUY	$51.85 - $73.49 $155,550 - $220,469	3,000 New	3,000 $208,000

Others Institutions Holding ACLX

# of Institutions

204

Shares Held

44.2M

Call Options Held

2.23M

Put Options Held

907K

Paradigm Biocapital Advisors LP New York, NY

4M
Shares

$302 Million
12.04% of portfolio
Perceptive Advisors LLC New York, NY

3.89M
Shares

$294 Million
8.48% of portfolio
Nea Management Company, LLC Timonium, MD

3.75M
Shares

$283 Million
23.89% of portfolio
Black Rock Inc. New York, NY

3.52M
Shares

$266 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.46M
Shares

$186 Million
0.0% of portfolio

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.31B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisory Alpha, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisory Alpha, LLC with notifications on news.

Account